

# Causal links between mitophagy and Alzheimer's disease: a Mendelian randomization study

Weijian Zhang<sup>1,2†</sup>, Wenjia Chen<sup>2&</sup>, Zhendong Guo<sup>1&</sup>, Hui Li<sup>2,3†\*</sup>

1 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, P.R.

China

2 Research Group of Standardization for Chinese medicine, Guangdong Provincial Hospital of

Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese

Medicine), Guangzhou, P.R. China

3 State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangzhou, P.R. China

\* Corresponding author. Address: Guangdong Provincial Hospital of Chinese Medicine (The

Second Affiliated Hospital of Guangzhou University of Chinese Medicine), No. 111 Dade Rd,

Yuexiu District, Guangzhou, Guangdong Province, China. Tel: +86-20-81887233. E-mail:

lihuitcm@126.com (H. Li).

## Background

Emerging evidence highlights the dysregulation of mitophagy, the process of clearing damaged mitochondria, as a potential contributor to Alzheimer's disease (AD) pathology. However, the precise mechanisms linking mitophagy to AD remain poorly understood. This study utilized summary-data-based Mendelian Randomization (SMR) combined with multi-omics data to explore the causal relationships between them, and to uncover potential epigenetic mechanisms of gene regulation.

## Methods

Mitophagy-related genes were identified through the integration of three databases, and transcriptomic data of AD patients were obtained from the Gene Expression Omnibus (GEO) database. A meta-analysis was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in AD. Through SMR tools, genome-wide association study (GWAS) summary data of AD from the GWAS Catalog (n=487,511) were separately integrated with expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) from blood and brain tissues to identify potentially causal genes and methylation sites. The findings from primary analysis were validated with data from the UK Biobank (n=301,478).

## Results

In total, 111 mitophagy-related genes were found to be differentially expressed in AD. The three-step SMR analysis identified two genes, PARL and BCL2L1, from blood tissues and three genes, ATG13, TOMM22, and SPATA33, from brain tissues as causal candidate genes associated with AD. The analysis pinpointed the possible epigenetic mechanisms, where specific methylation sites regulate the expression of these genes, potentially contributing to

their association with AD. All findings were successfully replicated in UK Biobank cohorts.

## Conclusions

The study emphasized the putatively causal relationships of mitophagy-related gene with AD.

These underlying pathogenic mechanisms could pave the way for new approaches in early detection and therapeutic intervention for AD.

**Keywords** Mitophagy, Alzheimer's disease, multi-omics, Mendelian randomization

# 1 Background

2 Alzheimer's disease (AD), the leading cause of dementia in older adults worldwide, is a  
3 progressive, age-related neurodegenerative disorder characterized by memory impairment,  
4 cognitive decline, personality changes, and language disorders [1]. Its major pathological  
5 features include amyloid beta (A $\beta$ ) plaques, neurofibrillary tangles of hyperphosphorylated  
6 tau (p-tau), and neuroinflammation. Although the etiology of AD remains poorly understood,  
7 it is generally believed that the multifaceted interplay of genetic variation, environmental  
8 factors, and lifestyle underpins the pathogenesis of AD, especially in sporadic cases [2].

9 The brain is one of the most energy-demanding organs, and brain cells are particularly  
10 vulnerable to mitochondrial damage [3]. The homeostasis of both neurons and glial cells is  
11 heavily dependent on the normal function of mitophagy, the central component of  
12 mitochondrial quality control [4]. Mitophagy refers to the selective degradation of defective  
13 mitochondria via the autophagy pathway [5]. By removing dysfunctional mitochondria in  
14 neurons and supporting glial cells, mitophagy not only reduces cellular damage caused by  
15 reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) leakage, but also enhances  
16 microglial phagocytosis of misfolded proteins like A $\beta$  and tau in neurodegenerative diseases  
17 [6]. This process helps to attenuate neuroinflammation, primarily induced by the release of  
18 pro-inflammatory cytokines or ROS, and maintain cellular homeostasis in AD models, thereby  
19 preventing bioenergetic failure and cell death [7].

20 Mounting evidence implicates that mitophagy is significantly dysregulated in the brains of AD  
21 patients and AD models, which may be one of the underlying contributors to the  
22 manifestation and pathophysiology of the disease [8]. Altered expression levels of several

23 mitophagy-related proteins, such as PINK1, p62, and LC3, have been observed in post-  
24 mortem human AD brains [9, 10].

25 Impaired mitophagy exacerbates oxidative damage and cellular energy depletion, leading to  
26 the aggregation of A $\beta$  and p-tau proteins, which in turn disrupt the mitophagy mechanism  
27 itself [11]. PINK1/Parkin signaling, involving proteins such as PINK1, Parkin, and p62, is an  
28 important pathway regulating mitophagy [12]. PINK1-deficient mAPP mice exhibited earlier  
29 and increased A $\beta$  accumulation, mitochondrial dysfunction, and cognitive impairment [13],  
30 while knocking out the p62 gene accelerated p-tau aggregation and neurodegeneration in  
31 PS19 mice [14]. Experimental evidence showed that upregulation of mitophagy-related  
32 proteins by genetic or pharmacological intervention could potentially increase mitophagy flux  
33 and ameliorate cognitive deficits in AD models [11, 13, 15].

34 Epigenetic modifications, particularly aberrant DNA methylation (DNAm) at CpG sites  
35 introduced by environmental factors, also play a vital role in AD development [16]. Both global  
36 and site-specific DNA hypomethylation have been found in post-mortem AD human brains  
37 and AD animal models [17, 18]. DNA methylation status in specific gene promoter or enhancer  
38 regions can affect A $\beta$  deposition and neurofibrillary tangle formation by altering gene  
39 expression [19]. For example, hypomethylation in the promoter of BACE1 or PSEN1, both  
40 integral to the A $\beta$  production, increases A $\beta$  aggregates in AD mice by upregulating the  
41 expression of these genes [20, 21].

42 Multiple genome-wide association studies (GWAS) in AD patients have successfully identified  
43 several genetic susceptibility loci related to mitochondrial function, including APOE, TOMM40,  
44 and CLU, especially in late-onset AD cases [22-24]. Furthermore, methylome-wide association

45 studies (MWAS) have also detected numerous AD-related DNA methylation marks, notably  
46 in genes such as APOE, MAPT, ANK1, and HOXA3 [25-27] .

47 Despite these findings, which have expanded our knowledge of the genetic architecture and  
48 epigenetic mechanisms in AD, the associations identified from GWAS and MWAS may not be  
49 the direct genetic causes of the disease due to confounding effects from environmental and  
50 genetic factors [28, 29]. The specific role of mitophagy-related genes and their regulatory  
51 elements in AD remains elusive.

52 Summary data-based Mendelian randomization (SMR) is a method that combines GWAS data  
53 with molecular trait data, such as expression quantitative trait loci (eQTL) and DNA  
54 methylation QTL (mQTL), with the objective of investigating putative causal relationships  
55 between the molecular signatures and diseases [30]. Given that AD is a progressive  
56 neurodegenerative disorder affecting the central nervous system [31], analyzing the putative  
57 effects of genetic variants on brain-expressed genes may yield more meaningful insights than  
58 blood-based analyses. Accordingly, we employed a three-step SMR approach, integrating AD  
59 GWAS summary statistics with eQTL/mQTL data from blood and brain tissues separately, to  
60 investigate gene expressions and DNAm sites potentially causally linked to AD.

61 Furthermore, the replication analysis using data from UK Biobank datasets validated findings  
62 from the primary analysis to ensure the robustness and reliability of the discovery.

## 63 **Methods**

### 64 **Study design**

65 The study design is illustrated in Figure 1. Initially, a meta-analysis of transcriptomic data was  
66 conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in

67 AD patients. Subsequently, the three-step SMR approach integrated AD GWAS summary  
68 statistics with eQTL/mQTL data of DEGs to identify potential causal relationships between  
69 these genes and AD. The SMR tests were conducted using eQTL and mQTL data from blood  
70 tissues, separately. Genes and methylation sites identified as significant in the primary analysis  
71 were then validated using data from UK Biobank.

72 **Fig 1.** Flowchart of the study. AD, Alzheimer’s disease; cis-eQTLs, cis-expression quantitative  
73 trait loci; cis-mQTL, cis-methylation quantitative trait loci; GWAS, Genome-wide association  
74 studies; SMR, summary-based Mendelian randomization; SNP, single nucleotide  
75 polymorphisms.

## 76 Data resources

77 Mitophagy-related genes were retrieved from the Gene Set Enrichment Analysis (GSEA),  
78 Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology Resource (GO) using  
79 the search terms “mitophagy”. Five microarray datasets for AD patients were gained from the  
80 Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) (S1 Table) [32-  
81 44].

82 In the primary analysis, GWAS summary statistics for AD from the GWAS Catalog were used,  
83 consisting of a total of 487,511 individuals, including 39,106 clinically diagnosed AD cases,  
84 46,828 proxy cases, and 401,577 controls [45]. These data were obtained from a meta-analysis  
85 of AD GWAS datasets collected across 15 European countries, combining results from the  
86 European Alzheimer & Dementia Biobank (EADB) consortium and the UK Biobank. The data  
87 can be accessed publicly via the GWAS Catalog - GCST90027158  
88 (<https://www.ebi.ac.uk/gwas/studies/GCST90027158>).

89 For external validation, we utilized GWAS summary data from the UK Biobank, encompassing  
90 a total of 301,478 individuals, with 25,392 AD cases and 276,086 controls [45]. The proxy-AD  
91 cases were determined based on questionnaire data in which individuals were asked if their  
92 parents had a diagnosis of dementia. All individuals analyzed in both the primary analysis and  
93 validation stages were of European ancestry.

94 Blood eQTL summary data of mitophagy-related genes were procured from eQTLGen, which  
95 contains statistics on blood gene expression from 31,684 individuals [46]. Blood mQTL data  
96 obtained through a meta-analysis implemented on two cohorts (n=1,980) [47]. Brain eQTL  
97 data were derived from BrainMeta v2 cis-eQTL summary data project (n= 2,865) [48], while  
98 the brain mQTL data were derived from the Brain-mMeta mQTL dataset (n = 1,160), generated  
99 through a meta-analysis that combined data from the studies by ROSMAP et al., Hannon et  
100 al., and Jaffe et al. [49]. This study focused on cis-eQTLs and cis-mQTLs, defined as single  
101 nucleotide polymorphisms (SNPs) located within a 1000 kb range upstream or downstream  
102 of the gene of interest.

103 For comprehensive details about the data used in the study, please refer to **Supporting**  
104 **information**.

## 105 **Statistical analysis**

### 106 **Identification of DEGs**

107 DEGs related to mitophagy between AD patients and healthy controls (HCs) were identified  
108 using linear regression models for each dataset, with adjustments for age, sex, and other  
109 relevant covariates to account for potential confounding factors. A meta-analysis with a fixed-  
110 effects model was then carried out using the R package *metafor* to integrate the DEGs from



111 individual datasets and derive the final set of DEGs [50].

## 112 SMR for detecting putative causal relationship

113 SMR tools were specifically designed to assess whether genetic variants influence complex  
114 traits through intermediate molecular traits, such as gene expression, DNA methylation, or  
115 protein abundance [30]. The 1000 Genomes European reference was used to calculate linkage  
116 disequilibrium [51], while the heterogeneity of dependent instruments (HEIDI) tests were  
117 employed for the assessment of heterogeneity [30].

118 The SMR analysis was conducted three times respectively using molecular QTL data from  
119 blood and brain tissues, with SNPs serving as genetic instrument variables in all three steps:  
120 (1) blood or brain eQTLs as exposures, with AD as the outcome; (2) blood or brain mQTLs as  
121 exposures, with AD as the outcome; (3) significant findings from step 1 as exposures, and  
122 findings from step 2 as outcomes. The significant causal associations were identified in  
123 accordance with the following criteria: (1) passing all three-step SMR with the threshold of  
124  $P_{SMR-multi} < 0.05$ ; (2) demonstrating genome-wide significance, with  $P < 1 \times 10^{-5}$  across all QTL  
125 datasets; and (3) displaying no significant heterogeneity ( $P_{HEIDI} > 0.05$ ).

## 126 Results

### 127 DEGs associated with mitophagy

128 After removing duplicates, 167 unique mitophagy-related genes were collected from three  
129 databases (S2 Table). The recognition of DEGs was conducted on each of the five microarray  
130 datasets to contrast the expression levels of transcripts between AD patients (n=401) and HCs  
131 (n=388) (S1 Table). After the meta-analysis of results from these five datasets, 111 mitophagy-  
132 related genes were recognized as DEGs in AD ( $P < 0.05$ ) (Fig 2 and S3 Table).

133 Fig 2. Volcano Plot of differentially expressed genes (DEGs) related to mitophagy in AD. A  
134 meta-analysis of five microarray datasets was conducted to compare gene expression  
135 between AD patients and healthy controls. In volcano plot, the x-axis represents meta-analysis  
136 effect sizes, while the y-axis shows the  $-\log$  of meta  $p$  value, indicating statistical significance.  
137 Red dots highlight the 111 significant differentially expressed genes (DEGs), while black dots  
138 represent non-significant genes. The dashed line marks the significance threshold at  $p < 0.05$ .

### 139 Integration of GWAS and mitophagy-related eQTL/mQTL data from 140 blood and brain tissues

141 As outlined previously, we sought to identify candidate causal genes for AD and elucidate the  
142 epigenetic mechanisms involved. Our three-step SMR analysis combined AD GWAS summary  
143 statistics from the GWAS Catalog with blood or brain cis-eQTLs/cis-mQTLs data of 111  
144 mitophagy-related DEGs.

145 Integrating blood eQTL data from the eQTLGen Consortium ( $n = 31,684$ ) with AD GWAS  
146 summary data identified 5 mitophagy-related genes ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ) (S4 Table).

147 Similarly, the integration of blood mQTL data ( $n = 1,980$ ) with the same AD GWAS data  
148 identified 676 CpG sites ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ) (S5 Table). Further analysis combining

149 the putative causal signals from the first two steps resulted in the identification of 6 CpG sites  
150 associated with the expression of two genes: PARL and BCL2L1 ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ )

151 (S6 Table).

152 In a similar manner, leveraging eQTL ( $n = 2,865$ ) and mQTL ( $n = 1,160$ ) data from brain tissues  
153 along with the same AD GWAS summary statistics, we identified 9 mitophagy-related genes

154 and 83 CpG sites ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ) (S7 and S8 Table). By combining findings from

155 transcriptome and methylome data, the third analysis filtered out 7 CpG sites that putatively  
156 regulate the expression of three genes: ATG13, TOMM22, and SPATA33 ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI}$   
157  $> 0.05$ ) (S9 Table).

158 The integration of multi-omics data from blood and brain tissues provides evidence  
159 supporting the causal relationships between mitophagy-related gene expression and AD  
160 pathogenesis, as shown in **Table 1**.

161 **Table 1. Associations of mitophagy-related gene expression with AD identified through three-**  
162 **step SMR analysis**

Analysis Type	Gene	Top SNP <sup>a</sup>	$P_{SMR-multi}$	$P_{HEIDI}$	nsnp HEIDI	betaSMR
Blood-based analysis	PARL	rs7644746	$4.69 \times 10^{-3}$	0.18	20	-0.13
	BCL2L1	rs6088962	$5.04 \times 10^{-3}$	0.11	20	0.41
Brain tissue analysis	ATG13	rs756343	$1.94 \times 10^{-2}$	0.15	20	0.03
	TOMM22	rs926299	$2.89 \times 10^{-2}$	0.61	20	0.05
	SPATA33	rs258334	$1.81 \times 10^{-3}$	0.10	20	-0.05

163 AD, Alzheimer's disease; SMR, summary-based Mendelian randomization; SNP, single  
164 nucleotide polymorphism;  $P_{SMR-multi}$ ,  $p$  value from multi-SNP-based SMR method;  $P_{HEIDI}$ ,  $p$   
165 value from HEIDI test (Heterogeneity in Dependent Instruments); nsnp HEIDI: The number of  
166 SNPs used in the HEIDI test;  $\beta_{SMR}$ , effect size from SMR analysis.

167 <sup>a</sup> Top SNP refers to the most significantly associated SNP with gene expression within a cis-  
168 eQTL region and it is used to estimate the effect of gene expression on trait.

169 **Plausible epigenetic regulation of mitophagy-related genes by DNA**  
170 **methylation in AD**

171 The three-step SMR analysis gave us an opportunity to speculate on the genetic regulation  
172 model of mitophagy-related genes in AD. One illustrative case is the PARL gene, which  
173 encodes a serine rhomboid protease located in the mitochondrial intermembrane space and  
174 is involved in regulating mitophagy by mediating the cleavage of PINK1 and PGAM5 [52, 53].  
175 DNAm site cg22921096 in the 5' untranslated region, 453 kbp downstream of PARL, was  
176 identified in the integration analysis of mQTL and AD GWAS summary statistics. The  
177 methylation level of this site exerted a positive effect on PARL expression ( $\beta_{SMR} = 0.07$ ) and  
178 a negative effect on AD ( $\beta_{SMR} = -0.03$ ). In addition, the PARL expression level was inversely  
179 related to the disease onset ( $\beta_{SMR} = -0.13$ ). Collectively, these results suggest that higher  
180 methylation level at this site upregulates the transcript level of PARL, potentially offering a  
181 protective effect against AD risk (Fig 3A).

182 ATG13, a key component of the ULK1 complex, is integral to the initiation of autophagy and  
183 mitophagy. Our analysis revealed a positive causal correlation between the ATG13 expression  
184 and DNAm site cg05585544, 957 kbp downstream of ATG13 ( $\beta_{SMR} = 0.13$ ). The elevated  
185 expression of ATG13 gene ( $\beta_{SMR} = 0.03$ ) and methylation levels of this CpG site ( $\beta_{SMR} =$   
186  $0.05$ ) potentially increased the susceptibility to AD. Therefore, it is hypothesized that the  
187 genetic variation modulates the DNAm status at this CpG site, leading to upregulation of  
188 ATG13 expression, which could contribute to a heightened risk of AD (Fig 3B).

189 **Fig 3. Three-step SMR analyses using molecular traits from blood and brain tissues.** SMR tools  
190 were used to prioritize the mitophagy-related genes potentially causally associated with AD,  
191 along with relevant epigenetic mechanisms of genetic regulation (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} >$   
192  $0.05$ ). The panels, from left to right, depict the following analysis results: SMR between gene

193 expression and AD GWAS on the left, SMR between gene methylation and AD GWAS in the  
194 middle, and SMR between gene methylation and gene expression. **Panels A** and **B** present  
195 the respective results for the genes PARL and ATG13. eQTL, expression quantitative trait loci;  
196 GWAS, Genome-wide association studies; mQTL, DNA methylation quantitative trait loci

## 197 External replication of mitophagy-related DEGs in AD GWAS summary 198 statistics from UK Biobank

199 For external replication, we made use of AD GWAS data from the UK Biobank (n=361,141) and  
200 integrated them with eQTLs and mQTLs of previously detected genes to validate our primary  
201 findings. All tested genes and relevant DNAm sites showed significant associations with AD  
202 in the UK Biobank cohort, thereby reinforcing the validity of our primary research results (S10  
203 Table).

## 204 Discussion

205 This is the first study to identify mitophagy-related genes and their corresponding  
206 methylation sites potentially causally linked to AD. Dysregulation of mitophagy results in the  
207 buildup of defective mitochondria, which contribute to progression of AD pathologies such  
208 as A $\beta$  aggregation, tau protein abnormalities, and neuroinflammation [5]. Targeting  
209 mitophagy has emerged as a promising therapeutic strategy, with animal model studies  
210 demonstrating its effectiveness in counteracting these pathological features and clinically  
211 improving cognitive deficits [54]. Since mitophagy-related DEGs in AD may either be a cause  
212 or an outcome of neurodegenerative processes [5, 55], it is essential to clarify the roles of  
213 these genes in AD development and their interactions with other biomolecules from a genetic  
214 perspective. By incorporating multi-omics data from different tissues through the SMR

215 method, we identified a potentially causal relationship between five mitophagy-related genes  
216 and AD, and investigated their genetic regulatory mechanisms via epigenomic modifications.  
217 Among the genes filtered out by the three-step SMR, most of them have been characterized  
218 in AD field. For instance, PARL, a susceptibility locus for AD, regulates mitophagy through the  
219 PINK1-Parkin pathway [56]. A recent genome-wide survival study and gene analysis have  
220 reported that the downregulation of PARL expression correlated with worsening clinical  
221 symptoms of AD [57]. Lower PARL expression has been shown to increase p-tau levels in  
222 different AD models, while overexpression of PARL reduced this accumulation in basic  
223 experiment [57]. Our study further identified the CpG methylation in the 5' untranslated  
224 region increased transcript level of PARL, potentially promoting its protective effect against  
225 AD ( $\beta_{SMR} = -0.13$ ).

226 Elevated levels of Bcl-xL have been observed in the brain tissues of AD patients [58]. The  
227 BCL2L1 gene encodes the Bcl-xL protein, an anti-apoptotic member of the Bcl-2 family, which  
228 modulates both apoptotic pathways and autophagy process, including mitophagy.  
229 Specifically, Bcl-xL inhibits mitophagy by binding to the BH3-like domain of Beclin 1, a key  
230 protein in the initiation and regulation of the process [59]. The inhibitory interaction between  
231 Beclin 1 and Bcl-xL could suppress activity of Beclin 1, thereby impairing mitophagy and  
232 exacerbating AD pathology [60].

233 ATG13, a vital component of the autophagy machinery, also plays an essential role in  
234 mitophagy processes [61]. At the onset of mitophagy, ATG13 forms the ULK complex with  
235 ULK1/2, ATG101 and FIP200, and the ULK complex initiates mitophagy by facilitating the  
236 formation and maturation of mitophagosomes [62], a structure that engulfs damaged

237 mitochondria and delivers them to lysosomes for degradation.

238 Another significant finding from the three-step SMR analysis in brain tissue is the identification  
239 of TOMM22, a critical receptor within the translocase of the outer mitochondrial membrane  
240 (TOMM) complex, responsible for importing Parkin into mitochondria under normal  
241 conditions [63]. Previous studies have demonstrated that the destabilization of TOMM22 and  
242 TOMM40 acts as the switch to trigger the mitophagy [64]. Moreover, overexpression of  
243 TOMM22 partially inhibits Parkin-mediated mitochondrial clearance, suggesting that the  
244 proper regulation of TOMM22 is important for maintaining mitochondrial quality control [64].  
245 Interestingly, SPATA33, identified as an autophagy mediator by recent experimental study,  
246 promotes the mitophagy in the male germline cells during spermatogenesis by interacting  
247 with the outer mitochondrial membrane protein VDAC2 and the autophagy-related protein  
248 ATG16L1 [65, 66]. The brain tissue analysis has suggested SPATA33 as a novel candidate gene  
249 potentially linked to AD development, although research in this area remains limited.

250 The strength of our investigation lies in the integration of multi-omics data from multiple  
251 tissues, providing a comprehensive analysis of the causal associations between mitophagy-  
252 related genes and AD. The three-step SMR with a more stringent statistical filtering criteria  
253 provided us stronger evidence to support our inference and enhanced our understanding of  
254 the genetic regulation mechanism involved in AD. Finally, all prioritized genes from the  
255 primary analysis were replicated in the other datasets, which further supported the reliability  
256 of the findings.

257 This study has some limitations that are worth acknowledging. First, eQTLs change in response  
258 to different cell states and environmental conditions [67]. Second, this study focused

259 exclusively on cis-eQTLs and cis-mQTLs. Third, the participants included in these datasets  
260 were individuals of European ancestry, and the lack of ancestral diversity limits the applicability  
261 of our findings to more ethnically diverse populations.

## 262 Conclusions

263 In conclusion, our study emphasized the potential causal links between mitophagy-related  
264 genes and AD. We identified biological mechanisms where DNA methylation modifications  
265 modulates the expression of specific mitophagy-related genes, thereby influencing the onset  
266 and progression of AD. These insights offer a deeper understanding of the pathogenesis of  
267 AD and hold significant implications for the development of novel therapeutic targets.

## 268 Supporting information

269 **S1 Table. Characteristics of 5 microarray datasets.**

270 **S2 Table. 167 mitophagy-related genes list.**

271 **S3 Table. Meta-analysis of 111 differentially expressed genes related to mitophagy from five**  
272 **datasets ( $p < 0.05$ ).** Estimate, combined effect size estimate; SE, standard error of the effect  
273 size estimate; CI.lb, lower bound of the 95% confidence interval; CI.ub, upper bound of the  
274 95% confidence interval.

275 **S4 Table. Summary-based Mendelian randomization (SMR) analysis from blood gene**  
276 **expression to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ).** ID, identifier; Chr, chromosome; bp, base  
277 pair position; SNP, single nucleotide polymorphisms; A1, effect (coded) allele; A2, other allele;  
278 Freq, frequency of effect allele; b, effect size; GWAS, Genome-Wide Association Studies; se,  
279 standard error; p, p-value; eQTL, expression quantitative trait locus; SMR, summary-based  
280 Mendelian randomization; SMR-multi, multi-SNP-based SMR; HEIDI, Heterogeneity in



281 Dependent Instruments test; nsnp HEIDI, number of SNPs used in the HEIDI test.

282 S5 Table. SMR analysis from blood DNA methylation to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ).

283 SMR, summary-based Mendelian randomization.

284 S6 Table. SMR analysis from blood DNA methylation to gene expression (all  $P_{SMR-multi} < 0.05$ ,

285  $P_{HEIDI} > 0.05$ ). Expo, exposure; ID, identifier; Chr, chromosome; bp: base pair position; Outco;

286 outcome; A1: effect allele; A2: other allele; Freq: frequency of the effect allele (A1); b: effect

287 size; se: standard error; p,  $p$  value; SMR, summary-based Mendelian randomization; SMR-

288 multi, multi-SNP-based SMR; HEIDI, Heterogeneity in Dependent Instruments test; nsnp HEIDI,

289 number of SNPs used in the HEIDI test.

290 S7 Table. SMR analysis from brain gene expression to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ).

291 S8 Table. SMR analysis from brain DNA methylation to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ).

292 S9 Table. SMR analysis from brain DNA methylation to gene expression (all  $P_{SMR-multi} < 0.05$ ,

293  $P_{HEIDI} > 0.05$ ).

294 S10 Table. External validation of the UK Biobank database

## 295 Acknowledgments

296 We thank all participants and investigators of the GWAS Catalog and UK Biobank.

## 297 Author Contributions

298 Conceptualization: Weijian Zhang, Wenjia Chen, Hui Li.

299 Data curation: Weijian Zhang, Zhendong Guo.

300 Formal analysis: Weijian Zhang, Wenjia Chen.

301 Methodology: Weijian Zhang, Zhendong Guo.

302 Software: Weijian Zhang, Zhendong Guo.

303 Validation: Zhendong Guo.

304 Visualization: Weijian Zhang.

305 Writing – original draft: Weijian Zhang, Wenjia Chen, Zhendong Guo.

306 Writing – review & editing: Weijian Zhang.

307 Funding acquisition: Hui Li.

## 308 Reference

309 1. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer's Disease: Epidemiology and  
310 Clinical Progression. *Neurol Ther.* 2022;11(2):553-69. Epub 20220314. doi: 10.1007/s40120-022-00338-  
311 8. PubMed PMID: 35286590; PubMed Central PMCID: PMC9095793.

312 2. Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's  
313 disease and Parkinson's disease. *Neurosci Biobehav Rev.* 2019;103:73-80. Epub 20190614. doi:  
314 10.1016/j.neubiorev.2019.06.018. PubMed PMID: 31207254; PubMed Central PMCID: PMC6700747.

315 3. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Ramos-Campo DJ, Belinchón-deMiguel  
316 P, Martínez-Guardado I, et al. Mitochondria and Brain Disease: A Comprehensive Review of Pathological  
317 Mechanisms and Therapeutic Opportunities. *Biomedicines.* 2023;11(9). Epub 20230907. doi:  
318 10.3390/biomedicines11092488. PubMed PMID: 37760929; PubMed Central PMCID: PMC10526226.

319 4. Yang X, Zhang Y, Luo J-x, Zhu T, Ran Z, Mu B-R, et al. Targeting mitophagy for neurological disorders  
320 treatment: advances in drugs and non-drug approaches. *Naunyn-Schmiedeberg's Archives of*  
321 *Pharmacology.* 2023;396(12):3503-28. doi: 10.1007/s00210-023-02636-w.

322 5. Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer's disease: Molecular defects and  
323 therapeutic approaches. *Mol Psychiatry.* 2023;28(1):202-16. doi: 10.1038/s41380-022-01631-6.

324 6. Magalhães JD, Fão L, Vilaça R, Cardoso SM, Rego AC. Macroautophagy and Mitophagy in  
325 Neurodegenerative Disorders: Focus on Therapeutic Interventions. *Biomedicines.* 2021;9(11). Epub  
326 20211105. doi: 10.3390/biomedicines9111625. PubMed PMID: 34829854; PubMed Central PMCID:  
327 PMC8615936.

328 7. Sukhorukov V, Voronkov D, Baranich T, Mudzhiri N, Magnaeva A, Illarioshkin S. Impaired  
329 Mitophagy in Neurons and Glial Cells during Aging and Age-Related Disorders. *Int J Mol Sci.* 2021;22(19).  
330 Epub 20210923. doi: 10.3390/ijms221910251. PubMed PMID: 34638589; PubMed Central PMCID:  
331 PMC8508639.

332 8. Sharma B, Pal D, Sharma U, Kumar A. Mitophagy: An Emergence of New Player in Alzheimer's  
333 Disease. *Front Mol Neurosci.* 2022;15:921908. Epub 20220706. doi: 10.3389/fnmol.2022.921908.  
334 PubMed PMID: 35875669; PubMed Central PMCID: PMC9296849.

335 9. Martín-Maestro P, Gargini R, García E, Perry G, Avila J, García-Escudero V. Slower Dynamics and  
336 Aged Mitochondria in Sporadic Alzheimer's Disease. *Oxid Med Cell Longev.* 2017;2017:9302761. Epub  
337 20171019. doi: 10.1155/2017/9302761. PubMed PMID: 29201274; PubMed Central PMCID:  
338 PMC5672147.

339 10. Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, et al.  
340 Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure,

- 341 function, and mitophagy defects in Alzheimer's disease models and human brains. *Acta Neuropathol.*  
342 2021;141(1):39-65. Epub 20201020. doi: 10.1007/s00401-020-02234-7. PubMed PMID: 33079262;  
343 PubMed Central PMCID: PMC7785558.
- 344 11. Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid- $\beta$  and  
345 tau pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat Neurosci.*  
346 2019;22(3):401-12. Epub 20190211. doi: 10.1038/s41593-018-0332-9. PubMed PMID: 30742114;  
347 PubMed Central PMCID: PMC6693625.
- 348 12. Zhou T-Y, Ma R-X, Li J, Zou B, Yang H, Ma R-Y, et al. Review of PINK1-Parkin-mediated  
349 mitochondrial autophagy in Alzheimer's disease. *Eur J Pharmacol.* 2023;959:176057. doi:  
350 <https://doi.org/10.1016/j.ejphar.2023.176057>.
- 351 13. Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, et al. PINK1 signalling rescues amyloid pathology and  
352 mitochondrial dysfunction in Alzheimer's disease. *Brain.* 2017;140(12):3233-51. doi:  
353 10.1093/brain/awx258. PubMed PMID: 29077793; PubMed Central PMCID: PMC5841141.
- 354 14. Ono M, Komatsu M, Ji B, Takado Y, Shimojo M, Minamihisamatsu T, et al. Central role for  
355 p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. *Aging Cell.*  
356 2022;21(7):e13615. Epub 20220605. doi: 10.1111/ace1.13615. PubMed PMID: 35662390; PubMed  
357 Central PMCID: PMC9282839.
- 358 15. Wang XJ, Qi L, Cheng YF, Ji XF, Chi TY, Liu P, et al. PINK1 overexpression prevents forskolin-induced  
359 tau hyperphosphorylation and oxidative stress in a rat model of Alzheimer's disease. *Acta Pharmacol*  
360 *Sin.* 2022;43(8):1916-27. Epub 20211210. doi: 10.1038/s41401-021-00810-5. PubMed PMID: 34893682;  
361 PubMed Central PMCID: PMC9343460.
- 362 16. Maity S, Farrell K, Navabpour S, Narayanan SN, Jarome TJ. Epigenetic Mechanisms in Memory and  
363 Cognitive Decline Associated with Aging and Alzheimer's Disease. *Int J Mol Sci.* 2021;22(22). Epub  
364 20211113. doi: 10.3390/ijms222212280. PubMed PMID: 34830163; PubMed Central PMCID:  
365 PMC8618067.
- 366 17. Cadena-del-Castillo C, Valdes-Quezada C, Carmona-Aldana F, Arias C, Bermúdez-Rattoni F,  
367 Recillas-Targa F. Age-dependent increment of hydroxymethylation in the brain cortex in the triple-  
368 transgenic mouse model of Alzheimer's disease. *J Alzheimers Dis.* 2014;41(3):845-54. doi: 10.3233/jad-  
369 132285. PubMed PMID: 24685633.
- 370 18. Shu L, Sun W, Li L, Xu Z, Lin L, Xie P, et al. Genome-wide alteration of 5-hydroxymethylcytosine  
371 in a mouse model of Alzheimer's disease. *BMC Genomics.* 2016;17:381. Epub 20160520. doi:  
372 10.1186/s12864-016-2731-1. PubMed PMID: 27207465; PubMed Central PMCID: PMC4875608.
- 373 19. De Plano LM, Saitta A, Oddo S, Caccamo A. Epigenetic Changes in Alzheimer's Disease: DNA  
374 Methylation and Histone Modification. *Cells.* 2024;13(8). Epub 20240421. doi: 10.3390/cells13080719.  
375 PubMed PMID: 38667333; PubMed Central PMCID: PMC11049073.
- 376 20. Monti N, Cavallaro RA, Stocco A, Nicolia V, Scarpa S, Kovacs GG, et al. CpG and non-CpG  
377 Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated  
378 with gene expression in human and murine brain. *Epigenetics.* 2020;15(8):781-99. Epub 20200205. doi:  
379 10.1080/15592294.2020.1722917. PubMed PMID: 32019393; PubMed Central PMCID: PMC7518704.
- 380 21. Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Iulita MF, Yang J, et al. Rescue of Early bace-1 and  
381 Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves  
382 Cognition in an Alzheimer's Model. *Sci Rep.* 2016;6:34051. Epub 20160929. doi: 10.1038/srep34051.  
383 PubMed PMID: 27681803; PubMed Central PMCID: PMC5041108.

- 384 22. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide  
385 association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet.*  
386 2021;53(9):1276-82. Epub 20210907. doi: 10.1038/s41588-021-00921-z. PubMed PMID: 34493870;  
387 PubMed Central PMCID: PMC10243600.
- 388 23. Brabec JL, Lara MK, Tyler AL, Mahoney JM. System-level analysis of Alzheimer's disease prioritizes  
389 candidate genes for neurodegeneration. *Frontiers in Genetics.* 2021;12:625246.
- 390 24. Sen A, Kalvakuri S, Bodmer R, Cox RT. Clueless, a protein required for mitochondrial function,  
391 interacts with the PINK1-Parkin complex in *Drosophila*. *Dis Model Mech.* 2015;8(6):577-89. Epub  
392 20150420. doi: 10.1242/dmm.019208. PubMed PMID: 26035866; PubMed Central PMCID:  
393 PMC4457034.
- 394 25. Migliore L, Coppede F. Gene-environment interactions in Alzheimer disease: the emerging role of  
395 epigenetics. *Nat Rev Neurol.* 2022;18(11):643-60. Epub 20220930. doi: 10.1038/s41582-022-00714-w.  
396 PubMed PMID: 36180553.
- 397 26. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG methylation in  
398 sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. *Hum Mol Genet.*  
399 2014;23(3):648-56. Epub 20130918. doi: 10.1093/hmg/ddt451. PubMed PMID: 24101602.
- 400 27. Li QS, Sun Y, Wang T. Epigenome-wide association study of Alzheimer's disease replicates 22  
401 differentially methylated positions and 30 differentially methylated regions. *Clin Epigenetics.*  
402 2020;12(1):149. Epub 20201017. doi: 10.1186/s13148-020-00944-z. PubMed PMID: 33069246;  
403 PubMed Central PMCID: PMC7568396.
- 404 28. Lin X, Barton S, Holbrook JD. How to make DNA methylome wide association studies more  
405 powerful. *Epigenomics.* 2016;8(8):1117-29. Epub 20160407. doi: 10.2217/epi-2016-0017. PubMed  
406 PMID: 27052998; PubMed Central PMCID: PMC5066141.
- 407 29. Young AS. Genome-wide association studies have problems due to confounding: Are family-based  
408 designs the answer? *PLoS Biol.* 2024;22(4):e3002568. Epub 20240412. doi:  
409 10.1371/journal.pbio.3002568. PubMed PMID: 38607978; PubMed Central PMCID: PMC11014432.
- 410 30. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from  
411 GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet.* 2016;48(5):481-7. Epub  
412 20160328. doi: 10.1038/ng.3538. PubMed PMID: 27019110.
- 413 31. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. *Mol*  
414 *Neurodegener.* 2019;14(1):32. doi: 10.1186/s13024-019-0333-5.
- 415 32. Hokama M, Oka S, Leon J, Ninomiya T, Honda H, Sasaki K, et al. Altered expression of diabetes-  
416 related genes in Alzheimer's disease brains: the Hisayama study. *Cereb Cortex.* 2014;24(9):2476-88.  
417 Epub 20130417. doi: 10.1093/cercor/bht101. PubMed PMID: 23595620; PubMed Central PMCID:  
418 PMC4128707.
- 419 33. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in  
420 the course of normal brain aging are sexually dimorphic. *Proc Natl Acad Sci U S A.* 2008;105(40):15605-  
421 10. Epub 20081001. doi: 10.1073/pnas.0806883105. PubMed PMID: 18832152; PubMed Central PMCID:  
422 PMC2563070.
- 423 34. Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW. Synaptic genes are  
424 extensively downregulated across multiple brain regions in normal human aging and Alzheimer's  
425 disease. *Neurobiol Aging.* 2013;34(6):1653-61. Epub 20121227. doi:  
426 10.1016/j.neurobiolaging.2012.11.024. PubMed PMID: 23273601; PubMed Central PMCID:  
427 PMC4022280.

- 428 35. Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate  
429 immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and  
430 neurodegeneration: a microarray study. *J Neuroinflammation*. 2012;9:179. Epub 20120723. doi:  
431 10.1186/1742-2094-9-179. PubMed PMID: 22824372; PubMed Central PMCID: PMC3419089.
- 432 36. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis  
433 of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. *PLoS One*.  
434 2010;5(9):e12538. Epub 20100908. doi: 10.1371/journal.pone.0012538. PubMed PMID: 20838618;  
435 PubMed Central PMCID: PMC2935886.
- 436 37. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine SN, et al. Accelerated  
437 neurodegeneration through chaperone-mediated oligomerization of tau. *J Clin Invest*.  
438 2013;123(10):4158-69. Epub 20130903. doi: 10.1172/jci69003. PubMed PMID: 23999428; PubMed  
439 Central PMCID: PMC3784538.
- 440 38. Sárvári M, Hrabovszky E, Kalló I, Solymosi N, Likó I, Berchtold N, et al. Menopause leads to elevated  
441 expression of macrophage-associated genes in the aging frontal cortex: rat and human studies identify  
442 strikingly similar changes. *J Neuroinflammation*. 2012;9:264. Epub 20121203. doi: 10.1186/1742-2094-  
443 9-264. PubMed PMID: 23206327; PubMed Central PMCID: PMC3558453.
- 444 39. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, et al. Gene expression profiles  
445 in anatomically and functionally distinct regions of the normal aged human brain. *Physiol Genomics*.  
446 2007;28(3):311-22. Epub 20061031. doi: 10.1152/physiolgenomics.00208.2006. PubMed PMID:  
447 17077275; PubMed Central PMCID: PMC2259385.
- 448 40. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is  
449 associated with reduced expression of energy metabolism genes in posterior cingulate neurons. *Proc  
450 Natl Acad Sci U S A*. 2008;105(11):4441-6. Epub 20080310. doi: 10.1073/pnas.0709259105. PubMed  
451 PMID: 18332434; PubMed Central PMCID: PMC2393743.
- 452 41. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. Multiscale  
453 Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical  
454 Networks by Human Herpesvirus. *Neuron*. 2018;99(1):64-82.e7. Epub 20180621. doi:  
455 10.1016/j.neuron.2018.05.023. PubMed PMID: 29937276; PubMed Central PMCID: PMC6551233.
- 456 42. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, et al. Altered neuronal gene  
457 expression in brain regions differentially affected by Alzheimer's disease: a reference data set. *Physiol  
458 Genomics*. 2008;33(2):240-56. Epub 20080212. doi: 10.1152/physiolgenomics.00242.2007. PubMed  
459 PMID: 18270320; PubMed Central PMCID: PMC2826117.
- 460 43. McKay EC, Beck JS, Khoo SK, Dykema KJ, Cottingham SL, Winn ME, et al. Peri-Infarct Upregulation  
461 of the Oxytocin Receptor in Vascular Dementia. *J Neuropathol Exp Neurol*. 2019;78(5):436-52. doi:  
462 10.1093/jnen/nlz023. PubMed PMID: 30990880; PubMed Central PMCID: PMC6467199.
- 463 44. Piras IS, Krate J, Delvaux E, Nolz J, Mastroeni DF, Persico AM, et al. Transcriptome Changes in the  
464 Alzheimer's Disease Middle Temporal Gyrus: Importance of RNA Metabolism and Mitochondria-  
465 Associated Membrane Genes. *J Alzheimers Dis*. 2019;70(3):691-713. doi: 10.3233/jad-181113. PubMed  
466 PMID: 31256118.
- 467 45. Bellenguez C, Küçükali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N, et al. New insights into  
468 the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet*. 2022;54(4):412-36. Epub  
469 20220404. doi: 10.1038/s41588-022-01024-z. PubMed PMID: 35379992; PubMed Central PMCID:  
470 PMC9005347.
- 471 46. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-

- 472 eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene  
473 expression. *Nat Genet.* 2021;53(9):1300-10. Epub 20210902. doi: 10.1038/s41588-021-00913-z.  
474 PubMed PMID: 34475573; PubMed Central PMCID: PMC8432599.
- 475 47. Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, et al. Integrative analysis of omics summary data  
476 reveals putative mechanisms underlying complex traits. *Nat Commun.* 2018;9(1):918. Epub 20180302.  
477 doi: 10.1038/s41467-018-03371-0. PubMed PMID: 29500431; PubMed Central PMCID: PMC5834629.
- 478 48. Qi T, Wu Y, Fang H, Zhang F, Liu S, Zeng J, et al. Genetic control of RNA splicing and its distinct role  
479 in complex trait variation. *Nat Genet.* 2022;54(9):1355-63. doi: 10.1038/s41588-022-01154-4.
- 480 49. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related traits  
481 using transcriptomic and methylomic data from blood. *Nature Communications.* 2018;9(1):2282. doi:  
482 10.1038/s41467-018-04558-1.
- 483 50. Viechtbauer W. Conducting Meta-Analyses in R with The metafor Package. *Journal of Statistical*  
484 *Software.* 2010;36. doi: 10.18637/jss.v036.i03.
- 485 51. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for  
486 human genetic variation. *Nature.* 2015;526(7571):68-74. doi: 10.1038/nature15393. PubMed PMID:  
487 26432245; PubMed Central PMCID: PMC4750478.
- 488 52. Sekine S, Kanamaru Y, Koike M, Nishihara A, Okada M, Kinoshita H, et al. Rhomboid protease PARL  
489 mediates the mitochondrial membrane potential loss-induced cleavage of PGAM5. *J Biol Chem.*  
490 2012;287(41):34635-45. Epub 20120822. doi: 10.1074/jbc.M112.357509. PubMed PMID: 22915595;  
491 PubMed Central PMCID: PMC3464569.
- 492 53. Lysyk L, Brassard R, Touret N, Lemieux MJ. PARL Protease: A Glimpse at Intramembrane  
493 Proteolysis in the Inner Mitochondrial Membrane. *J Mol Biol.* 2020;432(18):5052-62. Epub 20200419.  
494 doi: 10.1016/j.jmb.2020.04.006. PubMed PMID: 32320686.
- 495 54. Yang X, Zhang Y, Luo JX, Zhu T, Ran Z, Mu BR, et al. Targeting mitophagy for neurological disorders  
496 treatment: advances in drugs and non-drug approaches. *Naunyn Schmiedebergs Arch Pharmacol.*  
497 2023;396(12):3503-28. Epub 20230803. doi: 10.1007/s00210-023-02636-w. PubMed PMID: 37535076.
- 498 55. Jiménez-Loygorri JI, Boya P. Aging STINGs: mitophagy at the crossroads of neuroinflammation.  
499 *Autophagy.* 2024;20(7):1684-6. Epub 20240306. doi: 10.1080/15548627.2024.2322421. PubMed PMID:  
500 38411192; PubMed Central PMCID: PMC11210893.
- 501 56. Shi G, McQuibban GA. The Mitochondrial Rhomboid Protease PARL Is Regulated by PDK2 to  
502 Integrate Mitochondrial Quality Control and Metabolism. *Cell Rep.* 2017;18(6):1458-72. doi:  
503 10.1016/j.celrep.2017.01.029. PubMed PMID: 28178523.
- 504 57. Chen SD, Zhang W, Feng YW, Wu BS, Yang L, Zhang YR, et al. Genome-wide Survival Study Identifies  
505 PARL as a Novel Locus for Clinical Progression and Neurodegeneration in Alzheimer's Disease. *Biol*  
506 *Psychiatry.* 2023;94(9):732-42. Epub 20230303. doi: 10.1016/j.biopsych.2023.02.992. PubMed PMID:  
507 36870520.
- 508 58. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of  
509 proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. *Brain*  
510 *Res.* 1998;780(2):260-9. doi: 10.1016/s0006-8993(97)01202-x. PubMed PMID: 9507158.
- 511 59. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. *Cell*  
512 *Death Differ.* 2011;18(4):571-80. Epub 20110211. doi: 10.1038/cdd.2010.191. PubMed PMID:  
513 21311563; PubMed Central PMCID: PMC3131912.
- 514 60. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, et al. Impaired  
515 autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. *Prog*

516 Neurobiol. 2013;106-107:33-54. Epub 20130701. doi: 10.1016/j.pneurobio.2013.06.002. PubMed  
517 PMID: 23827971.

518 61. Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, et al. Hsp90-Cdc37  
519 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011;43(4):572-85. doi:  
520 10.1016/j.molcel.2011.06.018. PubMed PMID: 21855797; PubMed Central PMCID: PMC3485687.

521 62. Fujita K, Kedashiro S, Yagi T, Hisamoto N, Matsumoto K, Hanafusa H. The ULK complex-LRRK1 axis  
522 regulates Parkin-mediated mitophagy via Rab7 Ser-72 phosphorylation. J Cell Sci. 2022;135(23). Epub  
523 20221207. doi: 10.1242/jcs.260395. PubMed PMID: 36408770; PubMed Central PMCID: PMC9789397.

524 63. Pitt AS, Buchanan SK. A Biochemical and Structural Understanding of TOM Complex Interactions  
525 and Implications for Human Health and Disease. Cells. 2021;10(5). Epub 20210511. doi:  
526 10.3390/cells10051164. PubMed PMID: 34064787; PubMed Central PMCID: PMC8150904.

527 64. Bertolin G, Ferrando-Miguel R, Jacoupy M, Traver S, Grenier K, Greene AW, et al. The TOMM  
528 machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance.  
529 Autophagy. 2013;9(11):1801-17. Epub 20130905. doi: 10.4161/auto.25884. PubMed PMID: 24149440.

530 65. Xu X, Zhang Y, Cheng H, Zhou R. SPATA33 functions as a mitophagy receptor in mammalian  
531 germline. Autophagy. 2021;17(5):1284-6. Epub 20210405. doi: 10.1080/15548627.2021.1909836.  
532 PubMed PMID: 33818286; PubMed Central PMCID: PMC8143240.

533 66. Zhang Y, Xu X, Hu M, Wang X, Cheng H, Zhou R. SPATA33 is an autophagy mediator for cargo  
534 selectivity in germline mitophagy. Cell Death Differ. 2021;28(3):1076-90. Epub 20201021. doi:  
535 10.1038/s41418-020-00638-2. PubMed PMID: 33087875; PubMed Central PMCID: PMC7937689.

536 67. van der Wijst MGP, Brugge H, de Vries DH, Deelen P, Swertz MA, Franke L. Single-cell RNA  
537 sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. Nat Genet. 2018;50(4):493-7.  
538 Epub 20180402. doi: 10.1038/s41588-018-0089-9. PubMed PMID: 29610479; PubMed Central PMCID:  
539 PMC5905669.

540

541




Fig 2. Volcano plot of differentially expressed genes related to m



# cg22921096 (PARL)




Fig 3A. SMR between DNA methylation and AD (in the middle)

# ENSG00000175193 (PARL)




Fig 3A. SMR between PARL gene expression and AD (on the left)

# cg22921096 (PARL)




Fig 3A. SMR between DNA methylation and PARL gene expression

# ENSG00000175224.16 (ATG13)




Fig 3B. SMR between ATG13 and AD (on the left)

# cg05585544 (ATG13)

- ▲ top cis-eQTL
- cis-eQTL




Fig 3B. SMR between DNA methylation and AD (in the middle)

# cg05585544 (ATG13)




Fig 3B. SMR between DNA methylation and ATG13 (on the right)




Fig 1. Flowchart of the study.